NewsHK
Shareholder litigation has become a steady current in U.S.-listed biotech, tracking a sector where capital is scarce and governance scrutiny has tightened.
New York law firm Purcell & Lefkowitz LLP announced on July 16, 2026, that it is investigating Kymera Therapeutics, Inc.
(NASDAQ: KYMR) on behalf of the company's shareholders, seeking to determine whether the board of directors breached their fiduciary duties.
The scope of the Purcell & Lefkowitz probe The investigation centers on director conduct at Kymera Therapeutics.
Keep reading